The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

被引:0
作者
A K Burnett
R K Hills
A E Hunter
D Milligan
W J Kell
K Wheatley
J Yin
M F McMullin
H Dignum
D Bowen
N H Russell
机构
[1] Cardiff University School of Medicine,Department of Haematology
[2] Leicester Royal Infirmary,Department of Haematology
[3] Birmingham Heartlands Hospital,Department of Haematology
[4] University Hospital of Wales,Department of Haematology
[5] CRUK Clinical Trials Unit,Department of Haematology
[6] University of Birmingham,Department of Haematology
[7] Manchester Royal Infirmary,Department of Haematology
[8] Belfast City Hospital,Department of Haematology
[9] Queen Alexandra Hospital,Department of Haematology
[10] Leeds Teaching Hospitals NHS Trust,undefined
[11] Nottingham University Hospital NHS Trust,undefined
来源
Leukemia | 2013年 / 27卷
关键词
clinical trial; gemtuzumab ozogamicin; AML;
D O I
暂无
中图分类号
学科分类号
摘要
The treatment of older patients with acute myeloid leukaemia, who are not considered suitable for conventional intensive therapy, is unsatisfactory. Low-dose Ara-C(LDAC) has been established as superior to best supportive care, but only benefits the few patients who enter complete remission. Alternative or additional treatments are required to improve the situation. This randomised trial compared the addition of the immunoconjugate, gemtuzumab ozogamicin (GO), at a dose of 5 mg on day 1 of each course of LDAC, with the intention of improving the remission rate and consequently survival. Between June 2004 and June 2010, 495 patients entered the randomisation. The addition of GO significantly improved the remission rate (30% vs 17%; odds ratio(OR) 0.48 (0.32–0.73); P=0.006), but not the 12 month overall survival (25% vs 27%). The reason for the induction benefit failing to improve OS was two-fold: survival of patients in the LDAC arm who did not enter remission and survival after relapse were both superior in the LDAC arm. Although the addition of GO to LDAC doubled the remission rate it did not improve overall survival. Maintaining remission in older patients remains elusive.
引用
收藏
页码:75 / 81
页数:6
相关论文
共 149 条
[1]  
Walter RB(2011)Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment J Clin Oncol 29 4417-4423
[2]  
Othus M(1999)A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial Brit J Haematol 107 69-79
[3]  
Borthakur G(2007)Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences Blood 110 4606-4613
[4]  
Ravandi F(2007)The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia Br J Haematol 136 624-627
[5]  
Cortes-Franco JE(2011)Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes Lancet 376 2000-2008
[6]  
Pierce SA(2009)Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry Blood 113 4179-4187
[7]  
Wheatley K(1989)On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group J Clin Oncol 7 1268-1274
[8]  
Burnett AK(2009)The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial Br J Haematol 145 318-332
[9]  
Goldstone AH(2007)A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment Cancer 109 1114-1124
[10]  
Gray RG(2010)Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors J Clin Oncol 28 549-555